Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 and AZD6244 in Advanced Colorectal Carcinoma
NCT01333475Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206, selumetinib in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Mar 2011; status: completed.
02
Drugs
MK-2206selumetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01333475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333475.